Alternative coagulation promoters and gene therapies to drive hemophilia market

16 July 2019

Replacement factors are the current standard-of-care for both hemophilia A and B, representing 97% of the total sales of the hemophilia market in 2018.

However, according to analytics firm GlobalData, their market share is expected to decline to 70% by 2028 due to the introduction of alternative coagulation promoters (ACPs) and gene therapies, which promise to target significant areas of unmet need such as reducing the burden of intravenous infusions and reducing the risk of developing neutralizing antibodies, or inhibitors, against replacement therapies.

Within this scenario, the hemophilia A and B market is set to grow from $6.93 billion in 2018 to $9.29 billion in 2028 at a modest compound annual growth rate (CAGR) of 3%, says GlobalData.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK